McKesson to showcase pharmacy solutions at the American Society of Health-System Pharmacists mid-year meeting
SAN FRANCISCO — McKesson will be introducing hospital and health systems pharmacy leaders to new ideas and emerging solutions for their top issues at the American Society of Health-System Pharmacists Midyear Clinical Meeting 2013, which runs from Dec. 8 to 12. Organized under the theme “Learn, Network, Solve,” McKesson booth #849 will host solution demonstrations and live interviews, and pharmacy consulting experts will be on hand for one-on-one discussions designed to help pharmacy leaders drive better business health, the wholesaler stated.
“In addition to our exemplary distribution capabilities, McKesson is proven to bring material value to our hospital and health systems partners through pharmacy consulting,” stated Scott Miller, SVP McKesson Health Systems. “In today’s rapidly-shifting healthcare environment, hospital pharmacies are being forced to cut costs, improve efficiency and drive additional revenue. Our team of experts — comprised of former health system pharmacists — possesses the knowledge to identify opportunities, weigh alternatives and affect decisions to developing the appropriate course of action, working hand-in-hand with partners to seize the opportunities and achieve success.”
Attendees will have the opportunity to engage in one-on-one conversations with a McKesson Pharmacy Optimization consultant about the services available. And current McKesson customers will share their experience working with McKesson Pharmacy Optimization consultants. At McKesson’s booth, solutions to a number of pharmacy challenges will be spotlighted, including cost containment, 340B solutions, driving new revenue, achieving meaningful use, business insights, supply chain, ambulatory workflow and pharmacy workflow.
Software solutions that help pharmacy leaders increase the capture rate of discharge prescriptions and support medication adherence programs also will be highlighted. Experts will be available to explain technology solutions that combine pharmacy software, central fill and delivery services to support complex 340B and specialty programs.
Bartell Drugs enters retail clinic arena
SEATTLE — Bartell Drugs will open retail clinics at three of its stores under a partnership with a local health organization, the Seattle-based regional drug store chain said Monday.
Bartell said it would partner with Group Health Cooperative to open clinics at two stores in Seattle and one in the neighboring city of Bellevue, Wash., staffed by nurse practitioners from Group Health. The program is called CareClinic: Group Health at Bartell Drugs, or CareClinic for short, and the initial three clinics will open between January and March 2014.
"The CareClinics reflect our shared vision and commitment to customer service, innovation, improving health and wellness and community collaborations," Bartell chairman and CEO George Bartell said. "We see this as a continuation of Bartell Drugs’ vision to bring new products and services to our customers."
Services will be available to patients aged 2 and older and will provide care for minor illnesses and procedures like cold and flu, sinus infections, allergies, minor injuries, pinkeye, sore throat, headaches, head lice, ringworm, warts, sprains and strains, bronchitis, ear infections, urinary tract infections, diarrhea and intestinal infections.
Decisions of whether to expand the service will be based on how successful the initial three locations are, Bartell said.
Egalet, Shionogi to develop abuse-deterrent opioids
MALVERN, Pa. — Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.
The deal centers on the development and potential commercialization of experimental drugs containing the opioid painkiller hydrocodone.
Shionogi will pay Egalet $10 million upfront and purchase $15 million worth of its stock, as well as $300 million or more in milestone payments based on development and approval of products under the agreement. Egalet also is eligible to receive royalties and sales-based milestones of $100 million or more.